Kymera Therapeutics Inc. (KYMR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XKLS 
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.67 per share a year ago.
Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating
Kymera Therapeutics is a protein degradation specialist drug developer with promising Phase 1 and 2 stage protein degraders targeting various diseases. A partnership with Sanofi includes potential milestone payments of up to $1.48 billion for IRAK4 program, showing strong financial backing and support. I am expecting to see Positive data from Phase 2 studies of KT-474 expected in 1H25, with potential for significant share price increase and future M&A opportunities.
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Kymera Therapeutics Stock Is Soaring Today
Sanofi plans to expand phase 2 clinical studies evaluating Kymera's KT-474. This move could accelerate pivotal testing for the potential skin treatment.
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.
